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Summary 
Des-y-carboxy prothrombin (DCP), a prote-
in induced by vitamin K absence or antagonist-II (PIVKA-
II) was measured by an enzyme immunoassay (E-l023) 
using anti-DCP monoclonal antibody in 92 patients with 
various hepatobiliary diseases. Thirty-six of the 38 patients 
(94.7')1,,) with hepatocellular carcinoma (HCC) had abnor-
mal DCP levels greater than 0.1 arbitrary unit (AU)/ml, but 
only 18 of the 35 patients (51.4 %) had AFP greaterthan 100 
ngjml (suspicious levels for HCC). There was no correIa-
, tion between plasma or serum DCP and serum alpha-feto-
protein (AFP) levels. Serum alpha fetoprotein was elevated 
(above 20 ng/m\) in 23 of the 35 patients (65.7%), and DCP 
was elevated in all of the remaining 12 patients with normal 
AFP. DCP levels returned to normal levels following cura-
tive hepatic resection or orthotopic liver transplantation for 
HCC. DCP is a useful tumor marker in the diagnosis and 
postoperative monitoring of patients with H CC. 
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Alpha-fetoprotein (AFP) has long been used as 
a tumor marker for hepatocellular carcinoma (HCC). How-
ever, AFP is significantly elevated in the sera of less than half 
of the patients with HCC (1, 2). Another tumor marker, des-
gamma-carboxy prothrombin (DCP), has been reported to be 
useful in the diagnosis of HCC (3-6). This marker is also 
known as a protein induced by vitamin K absence or antago-
nist-II (PIVKA-Il) or abnormal prothrombin. 
DCP was originally found in the blood of 
patients who were deficient in vitamin K or who were receiving 
a vitamin K antagonist (3). In 1984 Liebman et al. (4) reported 
for the tirst time that serum DCP was elevated in patients with 
HCC. The method of DCP measurement has improved from a 
competitive radioimmunoassay with conventional poly-
clonal antibody, used by Liebman et aI., to an enzyme-linked 
immunosorbent assay (ELISA) using a monoclonal antibody 
prepared by a cell hybridization technique described by MOlo-
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hara et al. (5), and more recently to a double antibody sand-
wich system developed by Naraki et al. (6). 
In this report we examined the clinical signifi-
cance of plasma and serum DCP measurement in the diagno-
sis of HCC and the follow-up after curative surgery including 
orthotopic liver transplantation. Also reported here are other 
clinical conditions in which DCP may be elevated in the ab-
sence of HCC. 
Materials and methods 
Plasma DCP levels were measured in a total of 92 
patients. The histological diagnoses of 92 patients are listed in Table I. 
There were 46 patients with primary hepatic malignancy, 10 patients 
with metastatic tumors of various origins, and 36 patients with non-
cancerous liver diseases. The diagnosis was confirmed by pathological 
examination in all of the patients. The absence of HCC in the 27 
patients with cirrhosis and 7 patients with hepatitis was confirmed by a 
careful examination of the diseased liver after transplantation. 
Venous blood was drawn into a vacuum tube con-
taining a 3.8 % sodium citrate solution (9 parts of blood to one part of 
anticoagulant). The plasma was separated and immediately stored at 
- 20"C. In a few cases serum. rather than plasma. levels of DCP were 
measured. 
DCP was measured by the enzyme immunoassay 
Table 1 The histological diagnosis of 92 patients 
Hepatocellular carcinoma (nonFL-HCC) .. , .................. 34 
Fibrolamellar HCC ........................................ 4 
Hepatoblastoma ......................................... 1 
Cholangiocarcinoma ............ , ......................... 2 
Other primary hepatic malignancy ........................... 5 
EHE (2). angiosarcoma (1), neuroendOCrine tumor (1), 
leiomyosarcoma (1) 
Metastatic liver tumor ... , ............... , ..... , .......... 10 
Colon CA (5). pancreas CA (1). glucagonoma (1), 
somatostatinoma (1). duodenal papilla CA (1). 
esophagus CA (1) 
Benign hepatic tumor ., ............ , ...................... 2 
Cirrhosis of the liver (decompensated) ...................... 27 
Severe hepatitis .. , .. , .......... , ........................ ,7 
Total .. ' ............................................... 92 
EHE: Epithelioid hemangioendothelioma 
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(ElA) using a monoclonal antibody against DCP (E-I023: E1test 
MO?l;O p-n. Eisai Company, Ltd. Tokyo) (6). One arbitrary unit 
( I AU) is equivalent to I mg of purified prothrombin (7). Levels of 
DC P greater than 0.1 AU / mI were considered to be abnormally ele-
vated(8). 
Serum alpha-fetoprotein (AFP) was measured by 
AFP-EIA kit (Hybritech Inc. San Diego) and vitamin K-dependent 
blood coagulation factors (Factor II. VII. IX and X) were tested by 
Normotest (Hepaplastintest®. Eisai Company, Ltd. Tokyo). Serum 
total bilirubin was also measured at the same time. 
Results 
Plasma DCP levels were essentially equal (r -
0.97) to those in the serum, when they were measured simul-
taneously in 21 cases with liver tumor. 
The DCP levels of patients with hepatocellular 
carcinoma (HCC) and those with other diseases are sum-
marized in Figure I. DCP was elevated (greater than 0.1 
AU/ml) in 32 of the 34 patients with HCC (94.1 %). Elevated 
DCP levels were also observed in all of the 4 patients with fibr-
lamellar HCC and in one patient with hepatoblastoma. None 
of the 2 patients with peripheral cholangiocarcinoma or the 5 
patients with other primary hepatic malignancy had elevated 
DCP levels; nor did the 10 patients with metastatic liver tumor_ 
The DCP was slightly elevated in one patient who had a large 
liver cell adenoma and two lesions of focal nodular hyper-
plasia. 
The DCP was elevated in 9 of the 27 patients 
with liver cirrhosis (33.3'%). and in 2 of the 7 patients with 
hepatitis (28.6 u;(,) who did not have any malignancy. All these 
patients with liver cirrhosis and hepatitis had very poor he-
patic function. and were waiting for orthotopic liver transplan-
tation. 
Both AFP and DCP were measured at the same 
time in the 31 patients with non-fibrolamellar hepatocellular 
carcinoma (non-FL-HCC) and in the 4 patients with fi-
brolamellar HCC (FL-HCC). and the results are summarized 
in Figure 2. The AFP levels were higher than 20 ng/ml (normal 
AFP < ng/ml) in 23 (65.7%) of the 35 patients with hepato-
cellular carcinoma (HCC), and higher than 100 nglml (suspi-
cious for HCC) in 18 (51.4%) of them. On the other hand, the 
DCP levels were above 0.1 AU/ml in 33 (94.3%) of the 35 
patients with HCC. 
I t is worth noting that all 12 patients whose 
AFP levels were within normal range (below 20 ng/ml) and all 
17 patients with the AFP levels of less than 100 ng/ml had ele-
vated DCP levels. Thus. in all of the 35 patients with HCC. 
either AFP or DCP was abnormally elevated. All of the 4 
patients with tibrolamellar HCC had normal levels (less than 
20 ng/ml) of AFP. but their DCP levels were markedly ele-
vated. 
There was no statistically signficant correla-
tion between the AFP levels and the DCP levels (r - 0.08, 
Fig. 2). 
In the 12 patients with DCP-positive hepato-
cellular carcinoma (HCC), the plasma levels of DCP were 
measured after 4 hepatic resections and 8 orthotopic liver 
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Fig.4 Relationship between DCP and serum total bilirubin in 29 
patients with hepatocellular carcinoma (HCCl. 23 patients with liver 
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Fig. 5 Relationship between plasma DCP and Normotest levels in 
26 patients with hepatocellular carcinoma (HCCl. 27 patients with 
advanced liver cirrhosis (CIR) and 7 patients with hepatitis 
transplantations. As shown in Figure 3. the OCP levels 
decreased sharply after curative operation in all cases. and the 
levels returned to below 0.1 AU/ml within 3 days after trans-
plantation and 3 weeks after hepatic resection. 
In order to clarify the influence of vitamin K-
deficiency upon OCP levels the relationship between OCP 
and serum bilirubin was examined in Fig. 4. and that between 
OCP and Normotest in Fig. 5. High levels of serum total biliru-
hin were observed in many of the patients with advanced cir-
rhosis and severe hepatitis waiting for liver transplantation. 
and these patients had abnormal OCP levels in the absence of 
hepatic malignancy. In patients with hepatocellular carci-
noma (HCC) extreme hyperbilirubinemia was rare (Fig. 4). 
Low levels of N ormotest (\ess than 50 %) were observed in 21 
out of 34 patients (61.8 %) with advanced cirrhosis and severe 
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hepatitis. but only in 7 of the 26 patients (26.9 %) with hepato-
cellular carcinoma (HCC) (Fig. 5). 
Discussion 
Vitamin K. a fat soluble vitamin, is derived 
from food and intestinal micro flora. It is absorbed through the 
intestinal wall in the presence of bile and pancreatic juice. In 
the liver. vitamin K is required to convert the precursor of pro-
thrombin to active prothrombin by carboxylation of specific 
glutamic acid (Glu) residues in the precursor protein (3). The 
precursor (OCP) of prothrombin contains 10 Glu residues in 
the NH2-terminal domain. When these residues undergo car-
boxylation in the presence of vitamin K, they are converted to 
gamma carboxyglutamic acid (Gla) residues. The prothrom-
bin in which all Glu residues are converted to Gla residues is 
designated as normal prothrombin, and that with incomplete 
conversion as abnormal prothrombin (OCP or PIVKA-II). 
The exact mechanism by which abnormal pro-
thrombin (OCP) is produced by hepatocellular carcinoma 
(HCC), has not been determined. However. Okuda et al. (9) 
detected abnormal prothrombin in the culture medium of 
hepatoma cells. and Motohara et a!. (10) stained abnormal 
prothrombin in the hepatoblastoma cells. The normalization 
of abnormal prothrombin (OCP) after curative operation. as 
shown in Fig. 3. is further evidence that the HCC is a source of 
its production . 
The half-life of abnormal prothrombin (OCP) 
was reported to be approximately 30 hours in the patients of 
vitamin K deficiency (10). However. the half-life was 3 to 4 
days after curative hepatic resection in our four patients 
(Fig. 3). Rapid normalization ofOCP in our 8 patients after or-
thotopic liver transplantation (Fig. 3) may reflect the dilution 
or washout effect of a large amount of transfusion during the 
transplant procedure. The long half-life of OCP in cancer 
patients is possibly due either to the impaired hepatic function 
after major hepatic resection. or to the molecular structural 
difference ( 11) between OCP in vitamin K deficiency and that 
produced by cancer. Further investigation is needed to estab-
lish the mechanism of OCP production by cancer cells and to 
examine the possible difference in the molecular structure of 
OCP. 
Ninety-five percent of our 38 patients with 
hepatocellular carcinoma (HCC) had OCP levels greater than 
0.1 AU /m!. Fujiyama et al. (8) reported that 63 % of their 120 
patients with HCC had OCP levels greater than 0.1 AU/ml, 
and Hattori et al. (12) reported an incidence of 53 % in their 558 
patients with HCC. The difference in the positive rates be-
tween the present report and reports from Japan (8, 9, 12) may 
suggest that HCCs in the United States and those in Japan 
differ in terms of cell function or etiology, or else this may be 
due simply to the difference in tumor size or stage. And. 
indeed. small HCCs are diagnosed more frequently in Japan 
than in the United States. 
Our experience with OCP measurements 
clearly indicates that OCP is a better tumor marker for HCC 
than AFP (94.3 %. versus 51.4%). Japanese investigators (8, 9, 
12) reported thatAFP was elevated in 36.5% to 53.6% of their 
patients with HCC. and OCP in 48% to 57.7%, and that either 
AFP or OCP was elevated in 65.4% to 71.6%. They therefore 
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concluded that both AFP and DCP should be measured in 
patients with HCC. The present authors agree with this con-
clusion. 
Although DCP is an excellent tumor marker 
for HCC; it is not a tumor-specific antigen. There are other 
conditions in which DCP is abnormally high. Patients with ad-
vanced cirrhosis, severe hepatitis or obstructive jaundice also 
have elevated levels of DCP in the absence of HCC, as de-
scribed in the present report and in others (4, 8, 9, 12). Under 
these conditions, marked hyperbilirubinemia, a low Nor-
motest (indication of vitamin K-dependent coagulation fac-
tors II, VII, IX, and X deficiency) and/or very poor liver func-
tion tests, are also present. Therefore, the abnormal DCP 
levels must be carefully interpreted after detailed liver func-
tion tests and blood coagulation factors. 
Nevertheless, abnormal prothromin (DCP, 
PIVKA-II) is a useful tumor marker for hepatocellular carci-
noma. 
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